Pimecrolimus hydrate (100 nM) targets T-cells and mast cells and inhibits the production and release of cytokines and other inflammatory mediators, as well as the expression of signals essential for the activation of inflammatory T-lymphocytes[1].
Pimecrolimus hydrate (10, 30 mg/kg; p.o.; daily for 4 weeks) increases in absolute numbers of T lymphocytes in KLH-immunised rats compared with non-immunised animals[2].
References:
[1]. Grassberger M, et al. Pimecrolimus -- an anti-inflammatory drug targeting the skin. Exp Dermatol. 2004 Dec;13(12):721-30.
[2]. Roman D, et al. Determination of the effect of calcineurin inhibitors on the rat's immune system after KLH immunisation. Toxicol Lett. 2004 Apr 1;149(1-3):133-40.
[3]. Passeron T, et al. Treatment of oral erosive lichen planus with 1% pimecrolimus cream: a double-blind, randomized, prospective trial with measurement of pimecrolimus levels in the blood. Arch Dermatol. 2007 Apr;143(4):472-6.